PARADIGM-HF Responder Index (AWARD-Class) Calculator

Clinical calculation support · Verify results before clinical use

Patient characteristics

Choose the response that best matches the patient's baseline status.

— of 41
Aldosterone antagonist (MRA)-naive
Female sex
Heart-failure admission in the previous 12 months
Sinus rhythm
Diuretic-naive
NYHA functional class I–II
Reset calculator

About the AWARD-Class score

AWARD-Class is a clinical score proposed to identify ambulatory patients with heart failure who may demonstrate a super-response after starting sacubitril/valsartan. The derivation study was a retrospective analysis of 185 patients from two tertiary hospitals.

In the original study, super-response at 12 months required no heart-failure admission, death, or heart transplantation, together with a reduction in NT-proBNP of at least 50% and/or an increase in LVEF of at least 10 percentage points.

Score categories

Total scoreGroupObserved event rate
0–20Low probabilityApproximately 24%
21–30Intermediate probabilityApproximately 47%
31–41High probabilityApproximately 83%

Clinical use and limitations

  • This score predicts a study-defined response; it does not establish whether sacubitril/valsartan is indicated or safe for an individual patient.
  • The model's reported discrimination was modest (AUC 0.720 in the derivation cohort; 0.738 after internal bootstrap validation).
  • External validation and local calibration should be considered before applying these event rates to a different population.
  • Use current heart-failure guidelines, contraindications, blood pressure, renal function, potassium, tolerability, and clinical judgment when making treatment decisions.

References

Moliner-Abós C, Mojón Álvarez D, Rivas-Lasarte M, et al. A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure. Front Physiol. 2021;12:642117. DOI: 10.3389/fphys.2021.642117. PMID: 33679455.
McMurray JJV, Packer M, Desai AS, et al.; PARADIGM-HF Investigators and Committees. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371:993–1004. DOI: 10.1056/NEJMoa1409077. PMID: 25176015.

The first reference supports the AWARD-Class variables, weights, categories, and observed event rates. PARADIGM-HF is cited separately as the landmark randomized trial of sacubitril/valsartan versus enalapril, not as the derivation study for this score.

Clinical disclaimer: This calculator is an educational decision-support aid. AWARD-Class was developed in a small observational cohort and should not replace guideline-directed assessment, shared decision-making, or individualized clinical judgment. The reported group event rates may not generalize to other patient populations.